Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert back to old eating habits and put the weight back on, but there are also ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...